TVL is a very important issue for Ophthalmologists and Neurologists. In this presentation i want to make simple analysis to make a possible conclusion. I hope it will help the students.
Transient loss of vision is common clinical problem that ophthalmologists and neurologists can face. This presentation will highlight clinical approach and important causes with management.
Retinal vasculitis refers to the inflammation of the retinal vessel resulting in evident clinical manifestations i.e. vascular sheathing, leakage and occlusion. This presentation covers the etiology, pathogenesis, clinical features, diagnosis and management of this spectrum of retinal disease.
Transient loss of vision is common clinical problem that ophthalmologists and neurologists can face. This presentation will highlight clinical approach and important causes with management.
Retinal vasculitis refers to the inflammation of the retinal vessel resulting in evident clinical manifestations i.e. vascular sheathing, leakage and occlusion. This presentation covers the etiology, pathogenesis, clinical features, diagnosis and management of this spectrum of retinal disease.
Coats' disease, (also known as exudative retinitis or retinal telangiectasis, sometimes spelled Coates' disease), is a rare congenital, nonhereditary eye disorder, causing full or partial blindness, characterized by abnormal development of blood vessels behind the retina.
Most retinal surgeons are trained to create formal retinal drawings of the fundus.
Retinal drawings are useful to document pathology, although more and more people now prefer fundus photographs.
Can be used for serial follow up of patients to document changes in the pathology.
Ocular motility disorders: the Approach
Supra- vs infra- nuclear disorders and its related basic science
Other: synkinesis/aberrant regeneration, nystagmus
Nystagmus is a condition of involuntary (or voluntary, in some cases)eye movement, acquired in infancy or later in life, that in extremely rare cases may result in reduced or limited vision. Due to the involuntary movement of the eye, it has been called "dancing eyes"Contents
1 Causes
1.1 Early-onset nystagmus
1.2 Acquired nystagmus
1.3 Other causes
2 Diagnosis
2.1 Pathologic nystagmus
2.2 Physiological nystagmus
3 Treatment
4 Epidemiology
Discussion of clinical approach to typical (demyelnating) and atypical optic neuritis (immune/inflammatory/infectious) optic neuritis with evidence-based review.
Target: Ophthalmologists/Neurologists
A systematic approach with practical tips to diagnose and manage optic disc pallor. Disc pallor is often encountered in the routine clinical practice and remains a diagnostic enigma for most ophthalmologist. I illustrate the relevant practical points to be looked out for to deal with disc pallor.
Coats' disease, (also known as exudative retinitis or retinal telangiectasis, sometimes spelled Coates' disease), is a rare congenital, nonhereditary eye disorder, causing full or partial blindness, characterized by abnormal development of blood vessels behind the retina.
Most retinal surgeons are trained to create formal retinal drawings of the fundus.
Retinal drawings are useful to document pathology, although more and more people now prefer fundus photographs.
Can be used for serial follow up of patients to document changes in the pathology.
Ocular motility disorders: the Approach
Supra- vs infra- nuclear disorders and its related basic science
Other: synkinesis/aberrant regeneration, nystagmus
Nystagmus is a condition of involuntary (or voluntary, in some cases)eye movement, acquired in infancy or later in life, that in extremely rare cases may result in reduced or limited vision. Due to the involuntary movement of the eye, it has been called "dancing eyes"Contents
1 Causes
1.1 Early-onset nystagmus
1.2 Acquired nystagmus
1.3 Other causes
2 Diagnosis
2.1 Pathologic nystagmus
2.2 Physiological nystagmus
3 Treatment
4 Epidemiology
Discussion of clinical approach to typical (demyelnating) and atypical optic neuritis (immune/inflammatory/infectious) optic neuritis with evidence-based review.
Target: Ophthalmologists/Neurologists
A systematic approach with practical tips to diagnose and manage optic disc pallor. Disc pallor is often encountered in the routine clinical practice and remains a diagnostic enigma for most ophthalmologist. I illustrate the relevant practical points to be looked out for to deal with disc pallor.
Basavarajeeyam is an important text for ayurvedic physician belonging to andhra pradehs. It is a popular compendium in various parts of our country as well as in andhra pradesh. The content of the text was presented in sanskrit and telugu language (Bilingual). One of the most famous book in ayurvedic pharmaceutics and therapeutics. This book contains 25 chapters called as prakaranas. Many rasaoushadis were explained, pioneer of dhatu druti, nadi pareeksha, mutra pareeksha etc. Belongs to the period of 15-16 century. New diseases like upadamsha, phiranga rogas are explained.
Here is the updated list of Top Best Ayurvedic medicine for Gas and Indigestion and those are Gas-O-Go Syp for Dyspepsia | Lavizyme Syrup for Acidity | Yumzyme Hepatoprotective Capsules etc
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
DISSERTATION on NEW DRUG DISCOVERY AND DEVELOPMENT STAGES OF DRUG DISCOVERYNEHA GUPTA
The process of drug discovery and development is a complex and multi-step endeavor aimed at bringing new pharmaceutical drugs to market. It begins with identifying and validating a biological target, such as a protein, gene, or RNA, that is associated with a disease. This step involves understanding the target's role in the disease and confirming that modulating it can have therapeutic effects. The next stage, hit identification, employs high-throughput screening (HTS) and other methods to find compounds that interact with the target. Computational techniques may also be used to identify potential hits from large compound libraries.
Following hit identification, the hits are optimized to improve their efficacy, selectivity, and pharmacokinetic properties, resulting in lead compounds. These leads undergo further refinement to enhance their potency, reduce toxicity, and improve drug-like characteristics, creating drug candidates suitable for preclinical testing. In the preclinical development phase, drug candidates are tested in vitro (in cell cultures) and in vivo (in animal models) to evaluate their safety, efficacy, pharmacokinetics, and pharmacodynamics. Toxicology studies are conducted to assess potential risks.
Before clinical trials can begin, an Investigational New Drug (IND) application must be submitted to regulatory authorities. This application includes data from preclinical studies and plans for clinical trials. Clinical development involves human trials in three phases: Phase I tests the drug's safety and dosage in a small group of healthy volunteers, Phase II assesses the drug's efficacy and side effects in a larger group of patients with the target disease, and Phase III confirms the drug's efficacy and monitors adverse reactions in a large population, often compared to existing treatments.
After successful clinical trials, a New Drug Application (NDA) is submitted to regulatory authorities for approval, including all data from preclinical and clinical studies, as well as proposed labeling and manufacturing information. Regulatory authorities then review the NDA to ensure the drug is safe, effective, and of high quality, potentially requiring additional studies. Finally, after a drug is approved and marketed, it undergoes post-marketing surveillance, which includes continuous monitoring for long-term safety and effectiveness, pharmacovigilance, and reporting of any adverse effects.
Integrating Ayurveda into Parkinson’s Management: A Holistic ApproachAyurveda ForAll
Explore the benefits of combining Ayurveda with conventional Parkinson's treatments. Learn how a holistic approach can manage symptoms, enhance well-being, and balance body energies. Discover the steps to safely integrate Ayurvedic practices into your Parkinson’s care plan, including expert guidance on diet, herbal remedies, and lifestyle modifications.
Muktapishti is a traditional Ayurvedic preparation made from Shoditha Mukta (Purified Pearl), is believed to help regulate thyroid function and reduce symptoms of hyperthyroidism due to its cooling and balancing properties. Clinical evidence on its efficacy remains limited, necessitating further research to validate its therapeutic benefits.
Knee anatomy and clinical tests 2024.pdfvimalpl1234
This includes all relevant anatomy and clinical tests compiled from standard textbooks, Campbell,netter etc..It is comprehensive and best suited for orthopaedicians and orthopaedic residents.
share - Lions, tigers, AI and health misinformation, oh my!.pptxTina Purnat
• Pitfalls and pivots needed to use AI effectively in public health
• Evidence-based strategies to address health misinformation effectively
• Building trust with communities online and offline
• Equipping health professionals to address questions, concerns and health misinformation
• Assessing risk and mitigating harm from adverse health narratives in communities, health workforce and health system
2. Chairperson
Dr.Biswanath Ghosh
Associate Professor and Head
Department of Neurophthalmology
Moderator
Dr.Tarzeen Khadiza Shuchi
Assistant Professor
Department of Cornea
Presenter
Dr. S. M. Hasanuzzaman
FCPS Part ll Student, NIO&H
3. What is TVL?
Transient visual loss is the sudden loss
of visual function –
either partial or complete
either monocular or binocular
lasts less than 24 hrs.
4. Epidemiology:
• TVL is a very significant clinical
symptom
• Most important underlying cause is
retinal ischemia
• TVL with atheromatous carotid artery
disease have a 1 year risk of
recurrent stroke is 2%
• Patient with severe internal carotid
artery stenosis , risk of stroke is 16%
in 3 years
8. C. Optic nerve disorder:
• Acquired or congenital disc
disease(eg. papilloedema, disc
drusen)
• Compressive lesion of the intraorbital
optic nerve
• Demyelinating disease
9. D. Nonorganic Visual Loss
Malingering:
Willful feigning or exaggeration of
symptoms
Hysteria:
Subconscious expression of
nonorganic sign and symptoms
14. Diagnosis is done by:
Careful history taking
Clinical examinations
Lab investigations
15. History:
1. Monocular Vs Binocular:
Monocular loss implies a
prechiasmal problem
Binocular loss implies chiasmal or
retrochiasmal
Homonymous hemianopia is
misperceived by the patients as
monocular visual loss
16. Age:
<50 yr migraine or vasospasm is
the most likely cause of TVL
>50 yr cerebrovascular disease or
giant cell arteritis should be
considered
17. Duration of visual loss:
TVL from papilledema typically lasts
for few seconds
TVL from retinal emboli or transient
ischemic attacks lasts for several
minutes(< 15 minutes)
TVL from migraine typically lasts >
15 minutes
18. Pattern of onset:
An altitudinal onset of TVL(like a
curtain or shed descending) may
indicate embolic arterial occlusion
Concentric onset of TVL may
indicate vasospasm or neurologic
cause
Binocular visual disturbance having a
geometric quality suggest occipital
lobe dysfunction( migraine, seizure)
19. Associated symptoms:
Headache and positive visual
phenomena associated with TVL may
suggest migraine
Persistent headache with intracranial
noise may suggest increased
intracranial pressure
21. Global perfusion problems associated
with loss of consciousness, dizziness,
headache, diplopia ,dysarthria, focal
weakness
Skin, joint changes or Raynaud
phenomenon may suggest collagen
vascular disease
22. Precipitating factors:
TVL associated with postural
changes may suggest papilledema,
GCA and hypotension
Gaze evoked visual loss suggests an
orbital mass like hemangioma or
meningioma
Physical activity or elevated body
temperature with TVL may suggest
previous or current optic neuritis
29. Emboli
It is a major cause of TMVL
It can be observed with an
ophthalmoscope
Three common types are
1) Cholesterol(Hollenhorst plaque)
2) Platelet fibrin
3) Calcium
30. Cardiac emboli may arise from
ventricular aneurysm
Hypokinetic wall segments
Endocarditis
Valvular heart disease
Atrial fibrillation
31. Clinical Aspects of Retinal Emboli
Type Appearance Source
Cholesterol Yellow-orange
or copper color
Common or
internal carotid
artery
Platelet-fibrin Dull grey white
color
Walls of heart
specially valves
Calcium Chalky white
color
From heart,
great vessels,
calcific aortic or
mitral valve
32.
33. Examination techniques in
functional Visual loss:
Nonvisual task
Finger nose test
Optokinetic nystagmus drum
Mirror test
Confusion test
Fogging test
Duochrome test
35. Nervous system:
All patient should receive a detailed and
documented neurological examination.
We should give emphasis on
Cognitive and language function
Cranial nerve function
Facial and limb strength
Sensory function
Deep tendon reflex
Coordination
36. Investigations:
TMVL: to reveal an embolic cause:
1. Non invasive imaging:
• Carotid Ultrasonography
• Magnetic Resonance Angiography
• Computed Tomographic
Angiography
39. • Hypercoagulability / Hyperviscosity:
platelet count, protein C, Protein S,
Partial thromboplastin time, Anti
cardiolipin antibody, Serum protein
electrophoresis
47. Surgical management criteria
1. Male
2. Age >75 year
3. Previous history of TIA or stroke
4. Intermittent claudication
5. Stenosis 80% to 94%
6. Absence of collateral vessels on
angiography
48. Amourosis Fugax
The term Amaurosis Fugax not always
interchangeable with TVL.
Greek Amauroun means “To Darken”
Latin Fugax means “Fleeting”
The term Amaurosis Fugax is used to
describe TMVL due to retinal emboli
49. Take Home Message:
• Transient visual loss may lead to a
disease condition that can endanger
our life.
• So first and foremost patient must be
evaluated.
• Therefore we must educate the public
and medical colleagues about the
importance of getting an
ophthalmologic evaluation.